logo
This Survey Asked Neuroscientists If Memories Can Be Extracted From the Dead. Here's What They Said

This Survey Asked Neuroscientists If Memories Can Be Extracted From the Dead. Here's What They Said

Gizmodo19 hours ago
The allure and terror of transferring your consciousness to a computer has long been fodder for cyberpunk novels and billionaire-backed immortality startups. But a substantial chunk of neuroscientists think it might be possible to extract memories from a preserved brain and store those memories inside a computer, according to a new study.
The study, published in the journal PLOS One, suggests that most neuroscientists believe that memory has a physical basis and, on average, give a 40% probability that we might one day be able to emulate a human brain. But there was little consensus as to what exactly that physical basis is, highlighting just how little we know about what memories are made of.
The authors surveyed 312 neuroscientists—both memory experts and general neuroscientists—to get their thoughts on the feasibility of preserving a human brain and later extracting its memories. It was led by Ariel Zeleznikow-Johnston, a neuroscientist at Monash University in Australia and the author of The Future Loves You: How and Why We Should Abolish Death.
While the researchers wrote that the questions of memory extraction from preserved brains are 'strange and speculative,' they provide insight into how neuroscientists think about memory formation.
Results of the survey show that neuroscientists largely agree that memories have a physical substrate rather than relying on a dynamic process that ceases at preservation; they're likely stored in the synaptic connections between neurons, which strengthen and weaken with experience. The survey showed that 70% of neuroscientists agree that a physical, molecular record of a memory exists—stored in stable changes to neural connectivity and interactions between proteins and other cellular components—of which you could theoretically take a snapshot.
However, 'there was no clear consensus on exactly which neurophysiological feature or scale is critical for memory storage,' the authors wrote in the study. The surveyed scientists didn't agree on what resolution—from the atomic-level composition of biomolecules to nanometer-level resolution of subcellular structures—would be required to extract a memory from a preserved brain. This is largely due to the fact that, while most neuroscientists agree that memory has a physical basis, it's still up for debate exactly what that basis is.
The survey also asked whether existing tools could theoretically preserve the structure of a brain well enough to extract memories. Preserving a brain in such a way that the proteins and cells remain intact is tricky, since freezing can damage neural tissue. But one way neuroscientists could do this is through aldehyde-stabilized cryopreservation, a technique that combines chemical fixation with vitrification—the process of turning a substance into a glass-like solid by cooling it down rapidly. The study asked neuroscientists to assign a probability that memories could be extracted from a cryopreserved brain. The participants gave a wide range of estimates, but the median answer was around a 40% probability.
The authors asked the neuroscientists how probable it might be to emulate a whole brain—like, uploading and digitizing a person's brain onto a computer—from preserved neural tissue. That could open up the possibility of uploading your full self and consciousness into a machine. In this case, the median answer was again around 40%, though the authors note that the responses again varied widely.
'Admittedly, that's not 100 percent,' Zeleznikow-Johnston told IFLScience. 'That means that there's not full consensus in the community that yeah, definitely this will work, but it's not 0.1 percent, or 0.01 percent. That's a substantial chunk of neuroscientists who think there's a very real chance that it will work, and my guess is that actually that number will creep up over time as we get better at doing these brain implants, emulations, all these other things.'
Neuroscientists believe we're still a long way off from being able to emulate an entire human brain, according to the study. When asked when we might be able to emulate a human brain, the respondents gave a median answer of 2125.
Still, it's something to think about.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BigBear.ai Demonstrates AI-Driven Forecasting and Sentiment Analysis at Project Convergence
BigBear.ai Demonstrates AI-Driven Forecasting and Sentiment Analysis at Project Convergence

Yahoo

time2 hours ago

  • Yahoo

BigBear.ai Demonstrates AI-Driven Forecasting and Sentiment Analysis at Project Convergence

MCLEAN, Va., July 01, 2025--(BUSINESS WIRE)-- (NYSE: BBAI), a leading provider of mission-ready AI for defense and national security, today announced its participation in Project Convergence - Capstone 5 (PC-C5). PC-C5 is a combined joint and multinational experiment allowing partners and allies across Australia, Canada, France, Japan, New Zealand, United Kingdom, and all branches of the United States military to integrate resources and technologies in support of defense transformation efforts for future warfighters. The PC-C5 experiment presented opportunities for multinational forces to test Next Generation Command Control (NGC2) systems using relevant AI models. Virtual Anticipation Network (VANE) platform proved critical in helping forces quickly gain situational awareness and identify emerging threats. Operators highlighted its forecasting models, accurate sentiment analysis for detecting adversarial narratives, and metadata tagging for navigating unfamiliar environments and filtering relevant media. " is proud that VANE continues to demonstrate operational value in real-world exercises and experiments like PC-C5, involving forces from multiple nations," said Ryan Legge, President of National Security at "These environments validate the critical role AI plays in supporting faster, more accurate decision-making for warfighters. The feedback we received will inform future enhancements to better serve our mission partners." remains committed to equipping military and intelligence professionals with tools that can help improve how they perceive, predict, and act in complex operational environments. To learn more about VANE, visit About is a leading provider of AI-powered decision intelligence solutions and services for national security, defense, travel and trade, manufacturing and supply chains. Customers and partners rely on artificial intelligence and predictive analytics capabilities in highly complex, distributed, mission-based operating environments. Headquartered in McLean, Virginia, is a public company traded on the NYSE under the symbol BBAI. For more information, visit and follow on LinkedIn: @ To receive email communications from register here. Forward-Looking Statements This press release contains "forward-looking statements." Such statements include, but are not limited to, statements regarding the intended use of proceeds from the private placement and may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to the uncertainty of the projected financial information (including on a segment reporting basis); risks related to delays caused by factors outside of our control, including changes in fiscal or contracting policies or decreases in available government funding; changes in government programs or applicable requirements; budgetary constraints, including automatic reductions as a result of "sequestration" or similar measures and constraints imposed by any lapses in appropriations for the federal government or certain of its departments and agencies; influence by, or competition from, third parties with respect to pending, new, or existing contracts with government customers; our ability to successfully compete for and receive task orders and generate revenue under Indefinite Delivery/Indefinite Quantity contracts; potential delays or changes in the government appropriations or procurement processes, including as a result of events such as war, incidents of terrorism, natural disasters, and public health concerns or epidemics; and increased or unexpected costs or unanticipated delays caused by other factors outside of our control, such as performance failures of our subcontractors; risks related to the rollout of the business and the timing of expected business milestones; the effects of competition on our future business; our ability to issue equity or equity-linked securities in the future, and those factors discussed in the Company's reports and other documents filed with the SEC, including under the heading "Risk Factors." More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise, except as required by law. View source version on Contacts General/Sales: info@ Investors: investors@ Media: media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic
Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

Yahoo

time3 hours ago

  • Yahoo

Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

-- Milestone expands global reach and reinforces commitment to accessible, first-line infertility solutions -- ATLANTA, July 01, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products announces the achievement of regulatory approvals in Australia and New Zealand for its next-generation infertility solutions: FemaSeed® for first-line intratubal insemination treatment and FemVue® for diagnostic evaluation. 'Securing regulatory approvals in Australia and New Zealand mark another important step in expanding global access to our innovative infertility solutions,' said Kathy Lee-Sepsick, CEO and Founder of Femasys. 'With FemaSeed and FemVue, we are delivering much-needed, first-line options that address critical gaps in care for women struggling with infertility. These milestones not only validate the clinical value of our platform but also create meaningful commercial opportunities as we continue to grow revenue and broaden our global footprint.' About FemaSeed FemaSeed® is a next-generation artificial insemination solution that enhances fertilization by precisely delivering sperm to the fallopian tube, the natural site of conception. Offering a safe, accessible, and cost-effective first-line treatment, FemaSeed provides a more effective alternative to intrauterine insemination (IUI). In the pivotal clinical trial (NCT0468847), it achieved over double the pregnancy rates of IUI in cases of low male sperm count.1 FemaSeed is an affordable, less invasive, lower-risk option before IVF. It is authorized for use in the U.S., Europe, UK, Canada, Israel, Australia and New Zealand. Learn more at About FemVue FemVue® is a transformative, ultrasound-based alternative to radiologic imaging procedures for evaluating fallopian tube patency. It creates natural saline and air contrast for a safe, reliable, real-time assessment, all within the comfort of the gynecologist's office. When combined with a uterine cavity evaluation, it offers a comprehensive fertility exam. Because FemaSeed® requires at least one open fallopian tube, FemVue serves as an essential companion diagnostic to guide appropriate patient selection. It is authorized for use in the U.S., Japan, Europe, UK, Canada, Israel, Australia and New Zealand. Learn more at About FemasysFemasys is a leading biomedical innovator focused on addressing critical unmet needs in women's health with a broad, patent-protected portfolio of disruptive, accessible, in-office therapeutic and diagnostic products. As a U.S. manufacturer with global regulatory approvals, Femasys is actively commercializing its lead product innovations in the U.S. and key international markets. Femasys' fertility portfolio includes FemaSeed® Intratubal Insemination, a groundbreaking first-line infertility treatment and FemVue®, a companion diagnostic for fallopian tube assessment. Published clinical trial data show FemaSeed is over twice as effective as traditional IUI, with a comparable safety profile, and high patient and practitioner satisfaction.1 FemBloc® permanent birth control, the first and only non-surgical, in-office alternative to centuries-old surgical sterilization, has received regulatory approval in Europe. Commercialization of this highly cost effective, convenient and significantly safer approach will begin in Spain through engaged partnerships followed by select European countries. Alongside FemBloc, the FemChec® is a diagnostic product that enables an ultrasound-based test to confirm procedure success. Published data from initial clinical trials demonstrated compelling effectiveness, five-year safety, and high patient and practitioner satisfaction.2 For U.S. FDA approval, enrollment in the FINALE pivotal trial (NCT05977751) is ongoing. Learn more at or follow us on X, Facebook and LinkedIn. References1Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. doi: 10.33140/JGRM.08.02.08. 2Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S. C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12. doi: 10.33140/JGRM.09.01.05. Forward-Looking Statements This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'pending,' 'intend,' 'believe,' 'suggests,' 'potential,' 'hope,' or 'continue' or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law. Contacts: Investors: IR@ Media Contact: Media@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

When do we first feel pain?
When do we first feel pain?

Yahoo

time3 hours ago

  • Yahoo

When do we first feel pain?

At some point between conception and early childhood, pain makes its debut. But when exactly that happens remains one of medicine's most challenging questions. Some have claimed that foetuses as young as twelve weeks can already be seen wincing in agony, while others have flat-out denied that even infants show any true signs of pain until long after birth. New research from University College London offers fresh insights into this puzzle. By mapping the development of pain-processing networks in the brain – what researchers call the 'pain connectome' – scientists have begun to trace exactly when and how our capacity for pain emerges. What they discovered challenges simple answers about when pain 'begins'. Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK's latest coverage of news and research, from politics and business to the arts and sciences. The researchers used advanced brain imaging to compare the neural networks of foetuses and infants with those of adults, tracking how different components of pain processing mature over time. Until about 32 weeks after conception, all pain-related brain networks remain significantly underdeveloped compared with adult brains. But then development accelerates dramatically. The sensory aspects of pain – the basic detection of harmful stimuli – mature first, becoming functional around 34 to 36 weeks of pregnancy. The emotional components that make pain distressing follow shortly after, developing between 36 and 38 weeks. However, the cognitive centres responsible for consciously interpreting and evaluating pain lag far behind, and remain largely immature by the time of birth, about 40 weeks after conception. This staged development suggests that while late-term foetuses and newborns can detect and respond to harmful stimuli, they probably experience pain very differently from older children and adults. Most significantly, newborns probably can't consciously evaluate their pain – they can't form the thought: 'This hurts and it's bad!' These findings represent the latest chapter in a long-running scientific debate that has swung dramatically over the centuries, often with profound consequences for medical practice. For most physiologists in the 18th and 19th centuries, the perceived delicacy of the infant's body meant that it must be exquisitely sensitive to pain, so much so that some have had their doubts if infants ever felt anything else. Birth, in particular, was imagined to be an extremely painful event for a newborn. However, advances in embryology during the 1870s reversed this thinking. As scientists discovered that infant brains and nervous systems were far less developed than adult versions, many began questioning whether babies could truly feel pain at all. If the neural machinery wasn't fully formed, how could genuine pain experiences exist? This scepticism had troubling practical consequences. For nearly a century, many doctors performed surgery on infants without anaesthesia, convinced that their patients were essentially immune to suffering. The practice continued well into the 1980s in some medical centres. Towards the end of the 20th century, public outrage about the medical treatment of infants and new scientific results turned the tables yet again. It was found that newborns exhibited many of the signs (neurological, physiological and behavioural) of pain after all, and that, if anything, pain in infants had probably been underestimated. The reason why there has been endless disagreement about infant pain is that we cannot access their experiences directly. Sure, we can observe their behaviour and study their brains, but these are not the same thing. Pain is an experience, something that's felt in the privacy of a person's own mind, and that's inaccessible to anyone but the person whose pain it is. Of course, pain experiences are typically accompanied by telltale signs: be it the retraction of a body part from a sharp object or the increased activity of certain brain regions. Those we can measure. But the trouble is that no one behaviour or brain event is ever unambiguous. The fact that an infant pulls back their hand from a pin prick may mean that it experiences the pricking as painful, but it may also just be an unconscious reflex. Similarly, the fact that the brain is simultaneously showing pain-related activity may be a sign of pain, but it may also be that the processing unfolds entirely unconsciously. We simply don't know. Perhaps the infant knows. But even if they do, they can't tell us about their experiences yet, and until they can, scientists are left guessing. Fortunately, their guesses are becoming increasingly well informed, but for now, that is all they can be – guesses. What would it take to get certainty? Well, it would require an explanation that connects our brains and behaviour to our conscious experiences. But so far, no scientifically respectable explanation of this kind has been forthcoming. This article is republished from The Conversation under a Creative Commons license. Read the original article. Laurenz Casser receives funding from the Leverhulme Trust.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store